logo
Plus   Neg
Share
Email

Lilly Announces Interim Analysis From EMPRISE Real-world Study

Eli Lilly and Co. (LLY) said that a new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty or EMPRISE real-world study on effectiveness shows that Jardiance or empagliflozin was associated with a decreased risk of hospitalization for heart failure and a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors and GLP-1 receptor agonists.

The interim analysis included 190,000 adults in the U.S. with type 2 diabetes with and without cardiovascular disease.

In this new interim analysis, Jardiance was associated with a reduction in risk of hospitalization for heart failure of 41% compared with DPP-4 inhibitors and of 17% compared with GLP-1 receptor agonists.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
India-based Lupin Pharmaceuticals Inc. announced a recall of all batches of type 2 diabetes medication Metformin Hydrochloride Extended-Release Tablets, citing detection of N-Nitrosodimethylamine or NDMA, a probable human carcinogen. The move comes after many other drug companies called back Metformin tablets after the U.S. Food and Drug Administration or FDA recommended over NDMA concerns. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said that the current state of the COVID-19 pandemic in the U.S. is "really not good." The U.S. is the country worst-affected by the coronavirus and has recently seen a surge in coronavirus infections as lockdown restrictions are eased. Granules Pharmaceuticals, Inc. recalled twelve (12) lots of type 2 diabetes medication Metformin hydrochloride Extended-Release, in the form of oral film-coated tablets, for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement.
Follow RTT